Furthermore, elevated MAP17 levels are linked to a good response to platinum-based compounds in cervical and laryngeal carcinoma, and increased sensitivity to bortezomib in sarcomas, breast cancer, and lung cancer [13]. Here, PDZK1IP1 is linked to lung carcinoma.